Observational studyPediatric nephrology (Berlin, Germany)2026
Efficacy and safety of SOF/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study.
Observational study in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the efficacy and safety of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) in HCV-infected pediatric chronic kidney disease (CKD) patients on maintenance hemodialysis (HD).
methodsThis is a single-center, prospective single-arm observational exploratory study assessing the efficacy and safety of a 12-week course of sofosbuvir/ledipasvir (SOF/LDV) for the treatment of chronic HCV in Egyptian children and adolescents, 6-17 years old, who have CKD on regular HD. Potential adverse events (AE) were reported at baseline and during treatment administration using a detailed questionnaire. Sustained virological response (SVR12) was the primary study outcome.
resultsThe present study included 22 CKD patients on maintenance HD therapy. Their age ranged from 7.5 to 15.9 years with a median (IQR) of 12 (9.25-13.5) years. They were diagnosed with CKD stage 5 and scheduled for regular HD at a median (IQR) age of 6 (3.5-9) years (range 2-12 years). The median (IQR) baseline quantitative HCV RNA was 62,446 (6875-604,000) IU/L. During treatment, one patient experienced severe vomiting necessitating discontinuation of SOF/LDV. The remaining 21 patients completed the treatment course. The reported AE were all mild, and there were no reported serious adverse events. Nineteen out of 22 patients (86.4%) achieved SVR12.
conclusionsSOF/LDV was found to be effective in the treatment of HCV in children and adolescents with CKD on HD with SVR12 86.4%, with no serious adverse events recorded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.